Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.66 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.54 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.54 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407233 | 0.87 | MAOB (0.49) | MAOBPTPN1ABCG2ALDH1A1MEN1 | |
| SCHEMBL17237769 | 0.87 | MAOB (0.67) | MAOBPTPN1ABCG2ALDH1A1MEN1 | |
| SCHEMBL27705774 | 0.85 | MAOB (0.71) | MAOBPTPN1ABCG2ALDH1A1MEN1 | |
| SCHEMBL27705775 | 0.85 | MAOB (0.71) | MAOBPTPN1ABCG2ALDH1A1MEN1 | |
| SCHEMBL27799479 | 0.83 | HDAC8 (0.73) | MAOBPTPN1ABCG2ALDH1A1MEN1 | |
| SCHEMBL27799480 | 0.83 | HDAC8 (0.73) | MAOBPTPN1ABCG2ALDH1A1MEN1 | |
| SCHEMBL8052896 | 0.83 | MAOB (0.61) | MAOBPTPN1ABCG2ALDH1A1MEN1 | |
| SCHEMBL5126236 | 0.82 | MAOB (0.72) | MAOBPTPN1ABCG2ALDH1A1MEN1 | |
| SCHEMBL12808163 | 0.82 | MAOB (0.66) | MAOBABCG2ALDH1A1MEN1MAPT | |
| SCHEMBL30066572 | 0.82 | MAOB (0.69) | MAOBPTPN1ABCG2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| EP-2482823-A2 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES | SANOFI (FR) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011039338-A2 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES | SANOFI-AVENTIS (FR) | 2011-04-07 | — | — | WO | disclosed |
| US-20080108580-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-05-08 | — | — | US | disclosed |
| US-7288528-B2 | Aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-10-30 | — | — | US | disclosed |
| EP-1572707-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | Aventis Pharma Deutschland GmbH (DE) | 2005-09-14 | — | — | EP | disclosed |
| US-20050014704-A1 | Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004052902-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108580-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | SLC5A2, SLC5A1, UGGT1 | MAOB 666/4885PTPN1 922/4885ABCG2 16/4885 |
| US-20050014704-A1 | Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SLC5A2, SLC5A1, UGGT1 | MAOB 666/4885PTPN1 922/4885ABCG2 16/4885 |
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SLC5A1, SLC5A2, SOST | MAOB 2914/4885PTPN1 895/4885ABCG2 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.